单倍体相合造血干细胞移植治疗重型再生障碍性贫血患者的研究现状  

Research status on haploidentical hematopoietic stem cell transplantation in treatment of patients with severe aplastic anemia

作　　者：沈安令 周芳 Shen Anling;Zhou Fang(Graduate School of Jinzhou Medical University,Jinzhou 121000,Liaoning Province,China;Department of Hematology,the 96oth Hospital of the PLA Joint Logistics Support Force,Jinan 250031,Shandong Province,China)

机构地区：[1]锦州医科大学研究生学院,锦州121000 [2]中国人民解放军联勤保障部队第九六〇医院血液内科,济南250031

出　　处：《国际输血及血液学杂志》2023年第2期121-127,共7页International Journal of Blood Transfusion and Hematology

基　　金：山东省自然科学基金(ZR2022MH135)。

摘　　要：目前, 同胞全相合供者(MSD)-造血干细胞移植(HSCT)和免疫抑制疗法(IST)是重型再生障碍性贫血(SAA)的推荐一线治疗方法。其中, 由于MSD-HSCT具有造血重建快、无病生存(DFS)率高等优势, 成为具备移植条件的SAA患者的首选治疗方法。对于缺乏MSD的SAA患者, 目前单倍体相合HSCT(haplo-HSCT)取得满意的疗效, 逐渐成为其重要替代治疗选择。笔者从haplo-HSCT治疗SAA的适应证和疗效、供者选择和预后影响因素、预处理方案和移植物抗宿主病(GVHD)防治、造血干细胞(HSC)来源和数量及并发症等方面, 对haplo-HSCT治疗SAA的研究现状进行阐述。At present,matched sibling donor(MSD)-hematopoietic stem cell transplantation(HSCT)and immunotransplantation therapy(IST)are recommended for the first-line treatment of severe aplastic anemia(SAA).Among them,MSD-HSCT has the advantages of fast hematopoietic reconstruction and high disease-free survival(DFS)rate,making it the preferred treatment method for SAA patients suitable for transplantation.For SAA patients lacking of MSD,haploidentical HSCT(haplo-HSCT)has achieved satisfactory efficacy and has gradually become an important alternative treatment option.This article elaborates current research status of haplo-HSCT in the treatment of SAA from the aspects of efficacy and indications of haplo-HSCT,donor selection and prognostic factors,pre-treatment regimens,graft-versus-host disease(GVHD)prevention and treatment,as well as the source and number of hematopoietic stem cells(HSC),and complications.

关 键 词：贫血 再生障碍性 造血干细胞移植 单倍性 移植物抗宿主病 移植预处理 

分 类 号：R556.5[医药卫生—血液循环系统疾病]